DM
ELVN icon

Deerfield Management’s Enliven Therapeutics ELVN Stock Holding History

Deerfield Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,866
Closed -$671K – 149
2021
Q1 		$671K Sell
19,866
-124,601
-86% -$6.33M 0.01% 131
2020
Q4 		$12.7M Buy
144,467
+15,054
+12% +$1.26M 0.25% 93
2020
Q3 		$10.5M Buy
129,413
+23,413
+22% +$2.11M 0.26% 81
2020
Q2 		$11.7M Sell
106,000
-19,000
-15% -$2.13M 0.34% 72
2020
Q1 		$8.02M Buy
+125,000
New +$7.96M 0.25% 74

Other funds holding ELVN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deerfield Management's ELVN Position: Q2 2021 in Review

Deerfield Management sold out of Enliven Therapeutics (ELVN) in Q2 2021, closing a stake of 19,866 shares — an estimated $671K sold.

Deerfield Management first reported a position in ELVN in Q1 2020 and held it in 5 quarters. The position peaked at $12.7M in Q4 2020. 31 funds tracked by Wall St. Rank hold ELVN as of Q2 2021.

  • Deerfield Management reported no remaining Enliven Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Deerfield Management sold 19,866 Enliven Therapeutics shares in Q2 2021, an estimated $671K.
  • Deerfield Management first reported a position in Enliven Therapeutics in Q1 2020 and held it in 5 quarters.
  • Deerfield Management's Enliven Therapeutics position peaked at $12.7M in Q4 2020.
  • 31 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2021.

Based on Deerfield Management's 13F filing for Q2 2021, filed 16 Aug 2021.